A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2016
At a glance
- Drugs IW 1701 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Ironwood Pharmaceuticals
- 23 Apr 2016 Status changed from recruiting to completed.
- 18 Feb 2016 According to an Ironwood Pharmaceuticals media release, the company announced positive top-line data of IW-1701 for cardiovascular disease from this study.
- 03 Nov 2015 Results are expected to be reported in the first half of 2016, according to an Ironwood Pharmaceuticals media release.